ReviewJournal of neuroinflammation2012
Eosinophils in glioblastoma biology.
Review in Journal of neuroinflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Association of the interleukin-4Rα rs1801275 and rs1805015 polymorphisms with glioma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Eosinophil cationic protein-driven type 2 inflammation impairs olfactory function in a murine model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Profiling of rare immune cell populations and integrative analysis identify immune ecotypes in newly diagnosed meningiomas.Acta neuropathologica communications · 2026Article
- Post-traumatic meningioma or coincidental occurrence? A case report and critical review of the literature.Surgical neurology international · 2026Article
- Immune Cell Interplay in the Fight Against GBM.Cancers · 2025Review
- An Exploratory Study on a Potential Biomarker for Seizures in Autoimmune Encephalitis.Journal of inflammation research · 2025Article
- Article
- Comprehensive gene set enrichment and variation analyses identifyComputational and structural biotechnology journal · 2024Article
- DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma.Epigenetics · 2024Article
- Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment.Biomedicines · 2024Article
- "Vanishing" glioblastoma: A case report and review of the literature.Radiology case reports · 2024Article
- Causal effects of immune cells in glioblastoma: a Bayesian Mendelian Randomization study.Frontiers in neurology · 2024Article
- Article
- Article
- Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus.Cancer pathogenesis and therapy · 2023Review
- Identification of heterogeneous subtypes and a prognostic model for gliomas based on mitochondrial dysfunction and oxidative stress-related genes.Frontiers in immunology · 2023Article
- Peripheral eosinophil trends and clinical outcomes after non-traumatic subarachnoid hemorrhage.Frontiers in neurology · 2023Article
- Construction and Validation of an Immune-Related Risk Score Model for Survival Prediction in Glioblastoma.Frontiers in neurology · 2022Article
- Establishment and validation of a novel prognostic model for lower-grade glioma based on senescence-related genes.Frontiers in immunology · 2022Article
- Prognostic value of pretreatment circulating basophils in patients with glioblastoma.Neurosurgical review · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The development of this malignant glial lesion involves a multi-faceted process that results in a loss of genetic or epigenetic gene control, un-regulated cell growth, and immune tolerance. Of interest, atopic diseases are characterized by a lack of immune tolerance and are inversely associated with glioma risk. One cell type that is an established effector cell in the pathobiology of atopic disease is the eosinophil. In response to various stimuli, the eosinophil is able to produce cytotoxic granules, neuromediators, and pro-inflammatory cytokines as well as pro-fibrotic and angiogenic factors involved in pathogen clearance and tissue remodeling and repair. These various biological properties reveal that the eosinophil is a key immunoregulatory cell capable of influencing the activity of both innate and adaptive immune responses. Of central importance to this report is the observation that eosinophil migration to the brain occurs in response to traumatic brain injury and following certain immunotherapeutic treatments for GBM. Although eosinophils have been identified in various central nervous system pathologies, and are known to operate in wound/repair and tumorstatic models, the potential roles of eosinophils in GBM development and the tumor immunological response are only beginning to be recognized and are therefore the subject of the present review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.